Penn Highlands DuBois Installs Masimo SedLine Brain Function Monitoring

DUBOIS, PA and IRVINE, CA -- (Marketwired) -- 03/26/15 -- Penn Highlands DuBois -- with one of the best hospital safety scores as reported by the Leapfrog Group -- announced today it has selected Masimo's (NASDAQ: MASI) SedLine� brain function monitoring through the Root® patient monitoring and display platform to monitor patients under anesthesia or sedation.

Penn Highlands DuBois had been using Bispectral Index" (BIS") technology from Covidien.

"SedLine gives us more data on depths of anesthesia, and the Root technology platform allows us more additional Masimo MOC-9 technology options down the road to expand to fit our critical care monitoring needs," said Aaron DeVallance, MSN, CRNA, Director of Anesthesia at Penn Highlands. "The real-time numbers are faster to display -- so it gives us a rapid update on the anesthetic status of our patients, allowing for a faster response time and more timely decisions."

Root offers Masimo's SedLine® brain function monitoring, which provides four channels of EEG to help clinicians better understand the effects of anesthesia on the brain. SedLine measures the effects of anesthesia and sedation by monitoring both sides of the brain's electrical activity. As such, SedLine provides a wealth of EEG-based data, which can help clinicians monitor anesthesia.

"Time matters, of course, when it comes to clinical decisions," DeVallance added. "But SedLine also offers us cost savings. We're not over-sedating patients, so we're not wasting (anesthesia) gases."

"We are proud that after careful consideration, Penn Highlands DuBois selected Masimo Root with Sedline for its brain functioning monitoring needs," said Dr. Stephen Barker, M.D., Ph.D., Chairman of the Scientific Advisory Board of Masimo. "Sedline can help continuously monitor a patient's level of anesthesia and sedation in the OR and ICU settings, enabling clinicians to monitor anesthesia."

About Penn Highlands DuBois Penn Highlands DuBois offers residents of west central Pennsylvania a rare combination of technologically advanced health care in a warm, friendly environment. Widely recognized as one of the leading health centers of its kind in the commonwealth, Penn Highlands DuBois is an oasis of clinical and technical excellence, with a focus on patient-centered care. Visit https://www.phhealthcare.org/

About Masimo Masimo (NASDAQ: MASI) is the global leader in innovative noninvasive monitoring technologies that significantly improve patient care -- helping solve "unsolvable" problems. In 1995, the company debuted Measure-Through Motion and Low Perfusion pulse oximetry, known as Masimo SET®, which virtually eliminated false alarms and increased pulse oximetry's ability to detect life-threatening events. More than 100 independent and objective studies have shown that Masimo SET® outperforms other pulse oximetry technologies, even under the most challenging clinical conditions, including patient motion and low peripheral perfusion. In 2005, Masimo introduced rainbow SET® Pulse CO-Oximetry technology, allowing noninvasive and continuous monitoring of blood constituents that previously could only be measured invasively, including total hemoglobin (SpHb®), oxygen content (SpOC"), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), and Pleth Variability Index (PVI®), in addition to SpO2, pulse rate, and perfusion index (PI). Additional information about Masimo and its products may be found at www.masimo.com. @masimoinnovates

Forward-Looking Statements This press release includes forward-looking statements as defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, in connection with the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on current expectations about future events affecting us and are subject to risks and uncertainties, all of which are difficult to predict and many of which are beyond our control and could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements as a result of various risk factors, including, but not limited to: risks related to our belief that SedLine helps anesthesia providers deliver the desired level of targeted sedation throughout all phases of anesthesia; risks related to our assumptions of the repeatability of clinical results obtained; as well as other factors discussed in the "Risk Factors" section of our most recent reports filed with the Securities and Exchange Commission ("SEC"), which may be obtained for free at the SEC's website at www.sec.gov. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today's date. We do not undertake any obligation to update, amend or clarify these statements or the "Risk Factors" contained in our most recent reports filed with the SEC, whether as a result of new information, future events or otherwise, except as may be required under the applicable securities laws.

Masimo, SET, Signal Extraction Technology, Improving Patient Outcome and Reducing Cost of Care... by Taking Noninvasive Monitoring to New Sites and Applications, rainbow, SpHb, SpOC, SpCO, SpMet, PVI are trademarks or registered trademarks of Masimo.

Image Available: http://www2.marketwire.com/mw/frame_mw?attachid=2791099 Image Available: http://www2.marketwire.com/mw/frame_mw?attachid=2791101

Media Contacts:
John Brennan
Penn Highlands DuBois
(814) 298-0491
Email: [email protected]

Mike Drummond
Masimo
(949) 297-7434
[email protected]

Source: Masimo

You May Also Be Interested In

• Fisker (FSR) files form 10-K, sees more job cuts, reiterates going concern doubts
• B. Riley Financial (RILY) Files 10-K
• Centessa Pharmaceuticals (CNTA) Announces Pricing of $100 Million Public Offering of American Depositary Shares